By Mill Chart
Last update: Dec 26, 2023
Discover ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX), an undervalued stock highlighted by our stock screener. NASDAQ:RPRX showcases solid financial health and profitability while maintaining an appealing valuation. We'll explore the details.
An integral part of ChartMill's stock analysis is the Valuation Rating, which spans from 0 to 10. This rating evaluates diverse valuation factors, including price to earnings and cash flows, while considering the stock's profitability and growth. NASDAQ:RPRX has received a 8 out of 10:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:RPRX has achieved a 6:
ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NASDAQ:RPRX has earned a 5 out of 10:
ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:RPRX was assigned a score of 4 for growth:
More Decent Value stocks can be found in our Decent Value screener.
Our latest full fundamental report of RPRX contains the most current fundamental analsysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
ROYALTY PHARMA PLC- CL A
NASDAQ:RPRX (4/26/2024, 7:14:07 PM)
After market: 28 0 (0%)28
-0.11 (-0.39%)
Investors should take notice ofROYALTY PHARMA PLC- CL A (NASDAQ:RPRX)—it offers a great deal for the fundamentals it presents.
NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2024 financial...
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the...
Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside.
These Forbes 400 stocks have wealthy founders who run them with little fanfare or attention but are worth considering for your portfolio.
Discover three overlooked stocks on Wall Street with the potential for growth and diversification this April.
With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider.